ASX-listed Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has completed a A$203m (US$132m) placement to institutional investors. The offer price per new fully paid ordinary share was A$4.20, representing a 2.2%…
Australia: Clarity completes A$203m institutional placement
…
…






